Skip to main content
CRDF logo

CRDF · Cardiff Oncology, Inc. · Documents

Track CRDF — free
$0.87 +0.15 (+20.23%) Q4 2024 earnings call transcript
Market Cap
$56.49M
Shares
77.80M
Volume · Nov 16 15.55M Avg daily vol (3M) 591.25K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $593K down 13.2% 10-K filed Feb 24, 2026 Quarterly report New FY2026 Q3 10-Q filed Nov 12, 2026 Latest results New Onvansertib Phase 3 start potential in Q1 2027 8-K filed Nov 12, 2026 Earnings call Q4 2024 earnings call Held Feb 27, 2025
2026
Nov 12
Current report 8-K Events of Nov 10
Onvansertib Phase 3 start potential in Q1 2027

Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start.

Financial results
3 source passages
SAN DIEGO, Calif., November 12, 2026 — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update. Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Onvansertib achieved 72.2% response rate in first-line mCRC

Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.

Read from the MD&A section
3 source passages
Primary endpoint of confirmed objective response rate of 72.2% (13/18), compared with 42.1% (8/19) for FOLFIRI/bev alone, a 30 percentage point improvement over SoC. We have designed the registrational Phase 3 trial (CRDF-005) as a global randomized, controlled trial that will evaluate the safety and efficacy of onvansertib 30 mg + FOLFIRI/bev versus SoC FOLFIRI/bev as first-line therapy in patients with RAS-mutated mCRC. We expect to enroll approximately 640 patients across sites in the US, Europe and other regions. CARDIFF ONCOLOGY, INC. Open the document at this passage
Oct 22
Current report 8-K
Shareholder vote results

Cardiff Oncology stockholders approved increasing authorized capital stock from 170,000,000 to 320,000,000 and authorized common stock from 150,000,000 to 300,000,000 at the October 22, 2026 Special Meeting.

Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $104K ▼ 14.0% Net loss $9.23M Diluted EPS -$0.14
May 19
Current report 8-K
Other events AI summary on its way
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $41K ▼ 62.4% Net loss $12.35M Diluted EPS -$0.18
Apr 23
Proxy statement DEF 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $593K ▼ 13.2% Net loss $45.85M Diluted EPS -$0.69
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $683K ▲ 40.0% Net loss $45.43M Diluted EPS -$0.95
2024
Showing 1–50 of 192 documents
Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 63 filings 52 filers Visit website Investor relations